Meditsinski Tsentar Arkus Medikal A.D.

Research site

Bulgaria Nish 1, 5002 Veliko Tirnovo, Bulgaria

6 trials recruiting
Colitis ulcerative · Crohn's disease · Metabolic dysfunction-associated steatohepatitis
Adults and children

About Specializations

Meditsinski Tsentar Arkus Medikal A.D. in Veliko Tirnovo, Bulgaria specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Metabolic dysfunction-associated steatohepatitis, Non-alcoholic steatohepatitis, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases

The research team at Meditsinski Tsentar Arkus Medikal A.D. is conducting a trial focused on ulcerative colitis, aiming to assess a new therapy’s ability to induce and maintain clinical remission.

Induction therapy strategies
Maintenance of remission
Evaluation of patient-reported outcomes
Comparative effectiveness versus placebo

This work supports advances in digestive health and offers hope for patients with moderately to severely active disease.

Immune System Phenomena

A separate study at the same facility examines the safety profile of a novel monoclonal antibody in individuals with autoimmune hepatitis, focusing on tolerability and adverse event monitoring.

Comprehensive safety assessments
Tolerability over multiple dosing cycles
Liver function biomarker tracking
Placebo-controlled comparative analysis

Findings aim to expand therapeutic options for immune‑mediated liver disease and improve patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Nish 15002 Veliko TirnovoBulgaria

Open in maps ↗

Recruiting now: 6 trials
Conditions studied: 5

More sites in Veliko Tirnovo Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

7 clinical trials

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Duvakitug
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Duvakitug
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colitis ulcerative

Recruiting

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Duvakitug
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Autoimmune hepatitis

Recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Inebilizumab
Sponsor:Amgen Inc.

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy

Investigational

Study of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites